GlassScriptPhysician profile
Dan Td Nguyen
NPI 1598753618
$59,231.33
in general payments reported to CMS, 2019-2025
37 companies · $8,104 in 2025
The $8,104 reported for 2025 was more than what 85% of Neuroradiology providers received nationally (typical 2025 total: $278).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,428 · 2020: $3,512 · 2021: $3,364 · 2022: $8,830 · 2023: $16K · 2024: $14K · 2025: $8,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,500 · Travel and Lodging: $7,096 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,750 · Education: $3,500 · Consulting Fee: $2,938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,314.21 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,500.00 |
| Travel and Lodging | $7,095.52 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,750.00 |
| Education | $3,500.00 |
| Consulting Fee | $2,937.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stratus Medical, LLC | $20,426.05 | 2020-2025 | Nimbus |
| Si-Bone, INC. | $4,774.66 | 2019-2025 | |
| Mml US, INC. | $4,620.56 | 2021-2022 | |
| Saluda Medical Americas, INC. | $4,075.86 | 2023-2025 | Evoke, Evoke Scs |
| Medtronic, INC. | $3,702.39 | 2021-2025 | Synchromedii, Vanta Adaptivestim, Intellis Adaptivestim |
| Boston Scientific Corporation | $3,584.73 | 2020-2025 | Intracept, Clinical Trial Product |
| Medtronic USA, INC. | $3,117.56 | 2019-2020 | |
| Spr Therapeutics, INC | $2,548.28 | 2022-2025 | Sprint Pns System |
| Curonix LLC | $1,921.13 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Genesys Orthopedics Systems, L.L.C. | $1,563.72 | 2021-2022 | |
| Surgentec | $1,562.63 | 2022 | |
| Vertiflex, INC. | $1,088.36 | 2019 | |
| Abbott Laboratories | $1,088.10 | 2019-2023 | Proclaim |
| Stryker Corporation | $848.94 | 2019-2025 | Mild Device Kit, Optablate |
| Relievant Medsystems, INC. | $649.82 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $612.16 | 2019-2021 | |
| Nevro Corp. | $589.06 | 2020-2023 | Senza |
| Aurora Spine, INC. | $586.20 | 2022 | |
| Radius Health, INC. | $368.70 | 2019-2025 | Tymlos |
| Spinal Simplicity, LLC | $336.22 | 2020-2021 | |
| Stimwave Technologies Incorporated | $299.46 | 2019 | |
| Foundation Fusion Solutions, LLC | $214.64 | 2024 | |
| Vertos Medical, INC. | $202.95 | 2023 | Mild Device Kit |
| Baudax Bio INC. | $134.58 | 2022 | |
| Biotronik Nro, INC. | $54.50 | 2024 | Prospera |
| Amgen INC. | $46.05 | 2019-2020 | |
| Nalu Medical, INC. | $36.59 | 2022-2024 | Nalu Neurostimulation System |
| Bard Peripheral Vascular, INC. | $31.42 | 2025 | Trek |
| Merit Medical Systems INC | $21.95 | 2022 | |
| Baxter Healthcare | $20.83 | 2023 | Floseal |
| Hydrocision, INC. | $20.04 | 2020 | |
| Almatica Pharma LLC | $19.13 | 2025 | Teriparatide |
| Pacira Pharmaceuticals Incorporated | $18.36 | 2022 | |
| Novo Nordisk INC | $17.20 | 2024 | Rybelsus, Ozempic |
| Teleflex LLC | $15.06 | 2019 | |
| Amniox Medical, INC. | $13.44 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.